Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology
- PMID: 29796581
- PMCID: PMC6533968
- DOI: 10.1590/2175-8239-JBN-3807
Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology
Abstract
Scleroderma is an autoimmune disease that affects multiple systems. While pathophysiologic mechanisms governing the development of scleroderma are relatively poorly understood, advances in our understanding of the complement system are clarifying the role of complement pathways in the development of atypical hemolytic uremic syndrome and scleroderma renal crisis. The abundant similarities in their presentation as well as the clinical course are raising the possibility of a common underlying pathogenesis. Recent reports are emphasizing that complement pathways appear to be the unifying link. This article reviews the role of complement system in the development of atypical hemolytic uremic syndrome and scleroderma renal crisis, and calls for heightened awareness to the development of thrombotic angiopathy in patients with scleroderma.
A esclerodermia é uma doença autoimune que afeta múltiplos sistemas. Embora os mecanismos fisiopatológicos que regem o desenvolvimento da esclerodermia sejam relativamente pouco compreendidos, os avanços em nossa compreensão do sistema do complemento estão esclarecendo o papel das vias do complemento no desenvolvimento da síndrome urêmica hemolítica atípica e da crise renal da esclerodermia. As abundantes semelhanças em sua apresentação, bem como o curso clínico, estão aumentando a possibilidade de uma patogênese subjacente comum. Relatórios recentes estão enfatizando que as vias de complemento parecem ser o link unificador. Este artigo analisa o papel do sistema do complemento no desenvolvimento da síndrome urêmica hemolítica atípica e da crise renal na esclerodermia, e exige maior conscientização para com o desenvolvimento da angiopatia trombótica em pacientes com esclerodermia.
Conflict of interest statement
None of the authors has any disclosure except for AA who has served on speaker bureau for Alexion Pharmaceuticals. However, no grant/funding was obtained for this paper.
Similar articles
-
The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome.Am J Med Sci. 2016 Aug;352(2):177-90. doi: 10.1016/j.amjms.2016.05.003. Epub 2016 May 9. Am J Med Sci. 2016. PMID: 27524217 Review.
-
Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome.Exp Hematol. 2016 May;44(5):390-8. doi: 10.1016/j.exphem.2016.01.005. Epub 2016 Feb 26. Exp Hematol. 2016. PMID: 26921648 Free PMC article.
-
[Atypical hemolytic uremic syndrome caused by primary complement defects].Orv Hetil. 2018 Jun;159(23):929-936. doi: 10.1556/650.2018.31044. Orv Hetil. 2018. PMID: 29860884 Review. Hungarian.
-
Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.Am J Kidney Dis. 2015 Aug;66(2):331-6. doi: 10.1053/j.ajkd.2015.03.039. Epub 2015 May 23. Am J Kidney Dis. 2015. PMID: 26015278
-
Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.Am J Reprod Immunol. 2015 Oct;74(4):345-56. doi: 10.1111/aji.12404. Epub 2015 May 24. Am J Reprod Immunol. 2015. PMID: 26011580
Cited by
-
Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab.SAGE Open Med Case Rep. 2020 Aug 21;8:2050313X20952650. doi: 10.1177/2050313X20952650. eCollection 2020. SAGE Open Med Case Rep. 2020. PMID: 32913652 Free PMC article.
-
Post-transplant Thrombotic Microangiopathy.J Am Soc Nephrol. 2025 May 1;36(5):940-951. doi: 10.1681/ASN.0000000645. Epub 2025 Jan 31. J Am Soc Nephrol. 2025. PMID: 39888686 Review.
-
Atypical hemolytic uremic syndrome in the Colombian Caribbean: its particular characteristics.Int Urol Nephrol. 2022 Jun;54(6):1323-1330. doi: 10.1007/s11255-021-03011-5. Epub 2021 Oct 13. Int Urol Nephrol. 2022. PMID: 34643860 Free PMC article.
-
Targeting complement dysregulation: eculizumab in scleroderma renal crisis management-a case-based review.Rheumatol Int. 2024 Dec;44(12):3135-3140. doi: 10.1007/s00296-024-05689-z. Epub 2024 Aug 15. Rheumatol Int. 2024. PMID: 39147912 Review.
References
-
- LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–205. - PubMed
-
- Wollheim FA. Rheumatology. Vol. 44. Oxford: 2005. Classification of systemic sclerosis. Visions and reality; pp. 1212–1216. - PubMed
-
- Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am. 2003;29:315–333. - PubMed
-
- Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007;100:485–494. - PubMed
-
- Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D, International Scleroderma Renal Crisis Study Investigators Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum. 2014;43:666–672. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical